Search results for: 'Cancer Diagnostics Market'

This research service provides an analysis of the respiratory imaging diagnostics market in the United States and Europe. The service provides detailed analysis of the current and forecasted number of procedures, market size, and revenue forecast in respiratory diagnostics such as computed tomography, magnetic resonance imaging, positron emission t...

This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and ...

This study aims to cover the regulatory outlook and the diagnostics and drug approval process in the US, Europe, India, China, Japan and Brazil. Comparative analysis enables competitors to understand various regulatory hurdles and to position their products in pipeline better and plan for costs. Comparative analysis also enables an understanding of...

14 Mar 2022  |  North America  |  Market Outlook

Next-generation Diagnostics Outlook, 2022

Recovery in Routine Testing and Focus on Personalized Diagnostics to Propel Growth

Infographics

×

In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testin...

17 Jul 2017  |  North America  |  Market Research

US Oncology Diagnostics Market, Forecast to 2021

Manufacturers Increase Assay Development Focus Toward Screening, Prevention, and Therapy Selection

Infographics

×

Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolida...

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

This research service analyzes and provides forecasts of the US hematology diagnostics market from 2012 to 2017. The market is broadly classified into 2 major segments: analyzers and reagents. The US hematology market was sized using a bottom-up revenue model developed from the actual installed base of hematology analyzers in US laboratories, the d...

08 Oct 2021  |  North America  |  Market Research

Global Tissue Diagnostics (TDx) Growth Opportunities

Companion Diagnostics (CDx)-specific Advanced Staining and Anatomical Pathology Laboratory Information Systems (APLIS) to Drive Ma

Infographics

×

This research service provides an overview of the global TDx market and a 4-year forecast of it from 2021 to 2025. The market will reach $8,848.6 million in 2025, growing at a compound annual growth rate (CAGR) of 8.9% from 2020 to 2025. The advanced staining and anatomical pathology laboratory information management systems (APLIS) segments will g...

23 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...